公开(公告)号：US20220098229A1

公开(公告)日：2022-03-31

申请号：US17342694

申请日：2021-06-09

申请人： David J. Livingston ,  Andrew Carr ,  Philippe Fernandes

发明人： David J. Livingston ,  Andrew Carr ,  Philippe Fernandes

IPC分类号： C07H19/048

摘要： The invention relates to crystalline forms of a β-nicotinamide mononucleotide, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for nutraceutical, veterinary, and agriculturally-relevant uses.

公开(公告)号：US20170189434A1

公开(公告)日：2017-07-06

申请号：US15463683

申请日：2017-03-20

申请人： Karl D. Normington ,  David A. Sinclair ,  David J. Livingston ,  James M. McKearin ,  Bruce Szczpankiewicz ,  Jonathan N. Kremsky

发明人： Karl D. Normington ,  David A. Sinclair ,  David J. Livingston ,  James M. McKearin ,  Bruce Szczpankiewicz ,  Jonathan N. Kremsky

IPC分类号： A61K31/706

CPC分类号： A61K31/706 ,  A61K31/443 ,  A61K31/661 ,  A61K31/665 ,  A61K31/7052 ,  C07F9/06 ,  C07F9/547 ,  C07F9/65586 ,  C07F9/6561 ,  C07F9/65742 ,  C07H11/04 ,  C07H19/04 ,  C07H19/048

摘要： The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.

公开(公告)号：US08119631B2

公开(公告)日：2012-02-21

申请号：US12786221

申请日：2010-05-24

申请人： Mark James Batchelor ,  David Bebbington ,  Guy W. Bemis ,  Wolf Herman Fridman ,  Roger John Gillespie ,  Julian M. C. Golec ,  Yong Gu ,  David J. Lauffer ,  David J. Livingston ,  Saroop Singh Matharu ,  Michael D. Mullican ,  Mark A. Murcko ,  Robert Murdoch ,  Philip Nyce ,  Andrea L. C. Robidoux ,  Michael Su ,  M. Woods Wannamaker ,  Keith P. Wilson ,  Robert E. Zelle

发明人： Mark James Batchelor ,  David Bebbington ,  Guy W. Bemis ,  Wolf Herman Fridman ,  Roger John Gillespie ,  Julian M. C. Golec ,  Yong Gu ,  David J. Lauffer ,  David J. Livingston ,  Saroop Singh Matharu ,  Michael D. Mullican ,  Mark A. Murcko ,  Robert Murdoch ,  Philip Nyce ,  Andrea L. C. Robidoux ,  Michael Su ,  M. Woods Wannamaker ,  Keith P. Wilson ,  Robert E. Zelle

IPC分类号： C07D243/12 ,  C07D255/04 ,  C07D257/10 ,  C07D259/00 ,  A61K31/55 ,  A61P29/00

CPC分类号： C07D243/12 ,  A61K38/00 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07K5/0202 ,  C07K5/06139 ,  C07K5/0821

摘要： The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.

摘要翻译： 本发明涉及作为白介素-1和bgr的抑制剂的新型化合物。 转化酶。 本发明的ICE抑制剂的特征在于具体的结构和物理化学特征。 本发明还涉及包含这些化合物的药物组合物。 本发明的化合物和药物组合物特别适用于抑制ICE活性，因此可有利地用作抗IL-1，细胞凋亡，IGIF和IFN-γ介导的疾病，炎性疾病，自身免疫性疾病 破坏性骨病，增殖性疾病，感染性疾病，退行性疾病和坏死性疾病。 本发明还涉及使用本发明的化合物和组合物来抑制ICE活性，用于治疗白细胞介素-1，细胞凋亡，IGIF和IFN-γ介导的疾病以及减少IGIF和IFN-γ产生的方法。 本发明还涉及制备N-酰基氨基化合物的方法。

公开(公告)号：US20110178069A1

公开(公告)日：2011-07-21

申请号：US12786221

申请日：2010-05-24

申请人： Mark James Batchelor ,  David Bebbington ,  Guy W. Bemis ,  Wolf Herman Fridman ,  Roger John Gillespie ,  Julian M.C. Golec ,  Yong Gu ,  David J. Lauffer ,  David J. Livingston ,  Saroop Singh Matharu ,  Michael D. Mullican ,  Mark A. Murcko ,  Robert Murdoch ,  Philip Nyce ,  Andrea L.C. Robidoux ,  Michael Su ,  M. Woods Wannamaker ,  Keith P. Wilson ,  Robert E. Zelle

发明人： Mark James Batchelor ,  David Bebbington ,  Guy W. Bemis ,  Wolf Herman Fridman ,  Roger John Gillespie ,  Julian M.C. Golec ,  Yong Gu ,  David J. Lauffer ,  David J. Livingston ,  Saroop Singh Matharu ,  Michael D. Mullican ,  Mark A. Murcko ,  Robert Murdoch ,  Philip Nyce ,  Andrea L.C. Robidoux ,  Michael Su ,  M. Woods Wannamaker ,  Keith P. Wilson ,  Robert E. Zelle

IPC分类号： A61K31/5513 ,  C07D243/14 ,  C07D401/12 ,  A61P19/02 ,  A61P1/18 ,  A61P1/00 ,  A61P17/06

CPC分类号： C07D243/12 ,  A61K38/00 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07K5/0202 ,  C07K5/06139 ,  C07K5/0821

摘要： The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.

摘要翻译： 本发明涉及作为白介素-1和bgr的抑制剂的新型化合物。 转化酶。 本发明的ICE抑制剂的特征在于具体的结构和物理化学特征。 本发明还涉及包含这些化合物的药物组合物。 本发明的化合物和药物组合物特别适用于抑制ICE活性，因此可有利地用作抗IL-1，细胞凋亡，IGIF和IFN-γ介导的疾病，炎性疾病，自身免疫性疾病 破坏性骨病，增殖性疾病，感染性疾病，退行性疾病和坏死性疾病。 本发明还涉及使用本发明的化合物和组合物来抑制ICE活性，用于治疗白细胞介素-1，细胞凋亡，IGIF和IFN-γ介导的疾病以及减少IGIF和IFN-γ产生的方法。 本发明还涉及制备N-酰基氨基化合物的方法。

公开(公告)号：US20110059458A1

公开(公告)日：2011-03-10

申请号：US12918708

申请日：2009-02-20

申请人： Yumei Huang ,  James M. Coull ,  David J. Livingston

发明人： Yumei Huang ,  James M. Coull ,  David J. Livingston

IPC分类号： C12Q1/68 ,  C07H21/04

CPC分类号： C12Q1/6816 ,  C12N15/1068 ,  C12Q2563/155 ,  C12Q2563/131

摘要： The present invention relates compositions and methods that are useful in catalyzing DNA-Programmed Chemistry (or Nucleic Acid-templated chemistry) for use in therapeutic and diagnostic applications.

摘要翻译： 本发明涉及可用于催化用于治疗和诊断应用的DNA程序化学（或核酸模板化学）的组合物和方法。

公开(公告)号：US07772366B2

公开(公告)日：2010-08-10

申请号：US11901843

申请日：2007-09-18

申请人： Guy W. Bemis ,  Julian M. Golec ,  David J. Lauffer ,  Michael D. Mullican ,  Mark A. Murcko ,  David J. Livingston

发明人： Guy W. Bemis ,  Julian M. Golec ,  David J. Lauffer ,  Michael D. Mullican ,  Mark A. Murcko ,  David J. Livingston

IPC分类号： C07K38/07

CPC分类号： C07D243/08 ,  A61K38/00 ,  C07D243/12 ,  C07D263/56 ,  C07D413/04 ,  C07D487/04 ,  C07K5/0202 ,  C07K5/06052 ,  C07K5/0812

摘要： The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.

摘要翻译： 本发明涉及作为白介素-1和bgr的抑制剂的新型化合物。 转化酶。 本发明的ICE抑制剂的特征在于具体的结构和物理化学特征。 本发明还涉及包含这些化合物的药物组合物。 本发明的化合物和药物组合物特别适用于抑制ICE活性，因此可有利地用作抗白介素-1介导的疾病（包括炎性疾病，自身免疫性疾病和神经变性疾病）的药物。 本发明还涉及使用本发明的化合物和组合物来抑制ICE活性的方法和用于治疗白细胞介素-1介导的疾病的方法。

公开(公告)号：US20100169037A1

公开(公告)日：2010-07-01

申请号：US12345522

申请日：2008-12-29

申请人： Harland Glenn Hopkins ,  David J. Livingston

发明人： Harland Glenn Hopkins ,  David J. Livingston

IPC分类号： G01R27/28

CPC分类号： G11C29/50 ,  G11C29/12005 ,  G11C29/50004 ,  G11C29/56

摘要： In an embodiment, the invention provides a method for characterizing a threshold voltage of a flash memory cell. The method comprises generating a pulse train signal on flash memory IC, applying the pulse train signal to an external low-pass filter, and applying an output of the low-pass filter to the input of an external gain stage. An analog signal from the output of the gain stage is directed to a control gate of the flash memory cell. An electrical parameter of the flash memory cell is measured by an external tester.

摘要翻译： 在一个实施例中，本发明提供了用于表征闪存单元的阈值电压的方法。 该方法包括在闪速存储器IC上产生脉冲序列信号，将脉冲序列信号施加到外部低通滤波器，以及将低通滤波器的输出施加到外部增益级的输入。 来自增益级的输出的模拟信号被引导到闪存单元的控制栅极。 闪存单元的电气参数由外部测试仪测量。

公开(公告)号：US20100159446A1

公开(公告)日：2010-06-24

申请号：US12176798

申请日：2008-07-21

申请人： Lawrence A. Haff ,  Yumei Huang ,  Richard A. Martinelli ,  Benjamin A. Seigal ,  David J. Livingston ,  Wei-Chuan Sun

发明人： Lawrence A. Haff ,  Yumei Huang ,  Richard A. Martinelli ,  Benjamin A. Seigal ,  David J. Livingston ,  Wei-Chuan Sun

IPC分类号： C12Q1/68

CPC分类号： C12Q1/485 ,  C12Q1/6804 ,  G01N2333/705 ,  G01N2333/91215 ,  G01N2333/95 ,  G01N2500/02 ,  C12Q2565/101 ,  C12Q2563/179

摘要： The invention provides compositions and methods for the detection and/or quantification of biological targets (e.g., nucleic acids and proteins) by the nucleic acid-templated creation of one or more reaction products, for example, epitopes, enzyme substrates, enzyme activators, and ligands. The reaction products can be detected and/or quantitated after signal amplification using an amplification system.

摘要翻译： 本发明提供用于通过核酸模板产生一种或多种反应产物，例如表位，酶底物，酶活化剂和/或生物学靶标的检测和/或定量生物学靶标（例如核酸和蛋白质）的组合物和方法 配体。 可以使用扩增系统在信号放大后检测和/或定量反应产物。

公开(公告)号：US5973111A

公开(公告)日：1999-10-26

申请号：US828941

申请日：1997-03-28

申请人： Guy W. Bemis ,  Julian M. C. Golec ,  David J. Lauffer ,  Michael D. Mullican ,  Mark A. Murcko ,  David J. Livingston

发明人： Guy W. Bemis ,  Julian M. C. Golec ,  David J. Lauffer ,  Michael D. Mullican ,  Mark A. Murcko ,  David J. Livingston

IPC分类号： C07D263/24 ,  A61K31/42 ,  A61K31/421 ,  A61K38/00 ,  A61K45/00 ,  A61P25/00 ,  A61P29/00 ,  A61P37/00 ,  A61P43/00 ,  C07C229/22 ,  C07C233/41 ,  C07C233/83 ,  C07C311/30 ,  C07C317/26 ,  C07D521/00 ,  C07K5/02 ,  C07K5/023 ,  C07K5/04 ,  A61K38/07

CPC分类号： C07K5/0202 ,  A61K38/00

摘要： The present invention relates to novel classes of compounds which are inhibitors of interleukin-1.beta. converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.

公开(公告)号：US5874424A

公开(公告)日：1999-02-23

申请号：US598332

申请日：1996-02-08

申请人： Mark James Batchelor ,  David Bebbington ,  Guy W. Bemis ,  Wolf Herman Fridman ,  Roger John Gillespie ,  Julian M. C. Golec ,  David J. Lauffer ,  David J. Livingston ,  Saroop Singh Matharu ,  Michael D. Mullican ,  Mark A. Murcko ,  Robert Murdoch ,  Robert E. Zelle

发明人： Mark James Batchelor ,  David Bebbington ,  Guy W. Bemis ,  Wolf Herman Fridman ,  Roger John Gillespie ,  Julian M. C. Golec ,  David J. Lauffer ,  David J. Livingston ,  Saroop Singh Matharu ,  Michael D. Mullican ,  Mark A. Murcko ,  Robert Murdoch ,  Robert E. Zelle

IPC分类号： A61K38/00 ,  C07K5/02 ,  A61K31/55 ,  C07D243/02

CPC分类号： C07K5/0202 ,  A61K38/00

摘要： The present invention relates to novel classes of compounds which are inhibitors of interleukin-1.beta. converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against an IL-1 mediated disease, an apoptosis mediated disease, AML, CML, melanoma, myeloma, Kaposi's sarcoma, graft vs host disease, rheumatoid arthritis, inflammatory bowel disorder, psoriasis, osteoarthritis, myeloma, apoptosis, sepsis, rheumatoid arthritis, asthma, Alzheimer's disease, Parkinson's disease, and ischemic heart disease diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.